Bone Biologics Corp reports results for the quarter ended March 31 - Earnings Summary

• Bone Biologics Corp BBLG.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.31. The lone analyst forecast for the quarter was for a loss of 48 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Bone Biologics Corp's reported EPS for the quarter was a loss of 32 cents​.

• Bone Biologics Corp shares had fallen by 8.7% this quarter and lost 22.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• Wall Street's median 12-month price target for Bone Biologics Corp is $16.50

This summary was machine generated from LSEG data May 13 at 04:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)